Literature DB >> 186835

The effect of haloperidol on epinephrine-stimulated adenylate cyclase in humans.

R H Belmaker, R P Ebstein, H Schoenfeld, R Rimon.   

Abstract

Administration of epinephrine in man has been shown previously to lead to a rise in plasma cyclic AMP levels by activation of the beta-adrenergic-stimulated adenylate cyclase. Therapeutic doses of lithium in humans block the epinephrine-induced rise in plasma cyclic AMP levels, suggesting that lithium inhibits beta-adrenergic adenylate cyclase. In contrast, ten subjects receiving haloperidol, a druh also effective in the treatment of mania, show a mean rise in plasma cyclic AMP levels after epinephrine administration and the magnitude of the response is the same as for non-drug treated individuals. These findings are discussed in relation to the possible pharmacological mechanisms of action of lithium and haloperidol in the control of mania.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 186835     DOI: 10.1007/bf00427293

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  14 in total

Review 1.  Neuroleptics as a guideline to biological research in psychotic disorders.

Authors:  H M van Praag
Journal:  Compr Psychiatry       Date:  1975 Jan-Feb       Impact factor: 3.735

2.  Lithium inhibition of adrenaline-stimulated adenylate cyclase in humans.

Authors:  R Ebstein; R Belmaker; L Grunhaus; R Rimon
Journal:  Nature       Date:  1976-02-05       Impact factor: 49.962

3.  The sources of plasma cyclic AMP: studies in the rat using isoprenaline, nicotinic acid and glucagon.

Authors:  R C Strange; O D Mjos
Journal:  Eur J Clin Invest       Date:  1975-04       Impact factor: 4.686

4.  Drugs, neurotransmitters, and schizophrenia.

Authors:  S H Snyder; S P Banerjee; H I Yamamura; D Greenberg
Journal:  Science       Date:  1974-06-21       Impact factor: 47.728

5.  Comparison of lithium carbonate and chlorpromazine in the treatment of mania. Report of the Veterans Administration and National Institute of Mental Health Collaborative Study Group.

Authors:  R F Prien; E M Caffey; C J Klett
Journal:  Arch Gen Psychiatry       Date:  1972-02

6.  Modification by spychotropic drugs of the cyclic adenosine monophosphate response to norepinephrine in rat brain.

Authors:  G C Palmer; G A Robison; F Sulser
Journal:  Biochem Pharmacol       Date:  1971-01       Impact factor: 5.858

Review 7.  The catecholamine hypothesis of affective disorders: a review of supporting evidence.

Authors:  J J Schildkraut
Journal:  Am J Psychiatry       Date:  1965-11       Impact factor: 18.112

8.  A controlled study of lithium vs. chlorpromazine in acute schizophrenics.

Authors:  B Shopsin; S S Kim; S Gershon
Journal:  Br J Psychiatry       Date:  1971-10       Impact factor: 9.319

9.  Effects of catecholamines and adrenergic-blocking agents on plasma and urinary cyclic nucleotides in man.

Authors:  J H Ball; N I Kaminsky; J G Hardman; A E Broadus; E W Sutherland; G W Liddle
Journal:  J Clin Invest       Date:  1972-08       Impact factor: 14.808

10.  Cyclic adenosine monophosphate and norepinephrine: effects on transmembrane properties of cerebellar Purkinje cells.

Authors:  G R Siggins; A P Oliver; B J Hoffer; F E Bloom
Journal:  Science       Date:  1971-01-15       Impact factor: 47.728

View more
  2 in total

1.  Haloperidol and lithium blocking of the mood response to intravenous methylphenidate.

Authors:  D Wald; R P Ebstein; R H Belmaker
Journal:  Psychopharmacology (Berl)       Date:  1978-04-14       Impact factor: 4.530

2.  Subsensitivity of human beta-adrenergic adenylate cyclase after salbutamol treatment of depression.

Authors:  B Lerer; R P Ebstein; R H Belmaker
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.